hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06371482 id: Camel-01 briefTitle: Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) overallStatus: RECRUITING date: 2023-06-01 date: 2024-12-31 date: 2027-12-31 date: 2024-04-17 date: 2024-04-17 name: Hebei Medical University Fourth Hospital class: OTHER briefSummary: This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer. conditions: SCLC, Limited Stage studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 58 type: ESTIMATED name: Durvalumab name: Chemotherapy drug of EP regimen name: radiotherapy measure: Assessment of objective remission rate (ORR) in limited stage small cell lung cancer treated with durvalumab combined with chemoradiotherapy measure: Assessment of the incidence of treatment-related adverse events Incidence of Treatment-Emergent Adverse Events. measure: Assessment of overall survival (OS) in limited stage small cell lung cancer. measure: Assessment of progression-free survival (PFS) in limited stage small cell lung cancer. measure: Assessment of disease control rate (DCR) in limited stage small cell lung cancer. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fourth Hospital of Hebei Medical University status: RECRUITING city: Shijiazhuang state: Hebei zip: 050011 country: China name: Wenbin Shen, PhD role: CONTACT phone: +86 15831183879 email: wbshen1979@sina.com name: Hesong Wang, PhD role: CONTACT phone: +86 18810775196 email: wanghesongmz@163.com lat: 38.04139 lon: 114.47861 hasResults: False
nctId: NCT06371469 id: KAEK-769 briefTitle: Program of Health Behaviour Against to Cancer (PHeBAC) acronym: PHeBAC overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-07-20 date: 2024-08-20 date: 2024-04-17 date: 2024-04-18 name: Akdeniz University class: OTHER briefSummary: The European Code Against Cancer contains 12 recommendations to reduce the risk of cancer. It is estimated that about half of all cancers could be prevented if all recommendations are followed.
The aim of this study was to evaluate the effectiveness of the Program of Health Behaviour Against Cancer (PHeBAC) applied to mothers of children with intellectual disabilities in increasing the participation of mothers and their children with intellectual disabilities in cancer screenings and their health behaviors against cancer. The goal is to improve the preventive health behaviors of children with intellectual disabilities and their mothers against cancer and to increase the rate of participation in cancer screenings. Specific targets are; not smoking and not being exposed to smoking, increasing physical activity, healthy nutrition, limiting alcohol consumption, protection from sunlight, HPV vaccination and increasing participation in breast, cervical and colorectal cancer screenings. conditions: Cancer Prevention conditions: Health Behavior conditions: Disability, Intellectual conditions: Parents conditions: Cancer Screening conditions: Experimental Study Designs conditions: Mothers conditions: Disabilities Mental studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Mothers participating in the research will not know that they are in the intervention or control group. The data of the research will be collected by an independent investigator. In addition telephone support during the research process will be provided by the independent investigator, too whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: PHeBAC name: Control Group measure: Health Behaviors and Participation in Cancer Screenings Data Collection Form measure: Healthy Life Style Behaviors Scale II (Physical Activity and Nutrition Sub-Factors) measure: Sun Protection Behavior Scale sex: FEMALE minimumAge: 30 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06371456 id: Ain Shams university 111 briefTitle: A Non Invasive Confirmatory Sign for Correct Epidural Catheter Placement During Normal Vaginal Delivery overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-08-01 date: 2024-04-17 date: 2024-04-17 name: Ain Shams University class: OTHER briefSummary: Epidural anesthesia for pain control during normal vaginal delivery is a blind maneuver and so we need a confirmatory sign for being in the correct epidural space.
This sign may be associated with correct placement and good function of the epidural catheter. conditions: Normal Delivery Pain studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: epidural catheter placement measure: appearance of the dew sign measure: epidurogram measure: visual analogue score measure: mean blood pressure measure: mean blood pressure measure: heart rate measure: heart rate sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06371443 id: ayselkokcudogan briefTitle: Suction and Swalloing Exercises for Premature Babies overallStatus: COMPLETED date: 2021-12-03 date: 2022-06-01 date: 2022-08-01 date: 2024-04-17 date: 2024-04-17 name: Istanbul Medipol University Hospital class: OTHER briefSummary: Underdeveloped oral structures of preterm infants cause feeding problems. Therefore, the development of sucking reflexes of premature babies should be supported.
The study was conducted as a randomized controlled experimental trial in the NICU of a public hospital in Istanbul. The study sample consisted of 82 premature infants. Of these infants, 41 were assigned to the experimental group and 41 to the control group. Study data were collected using the investigator-developed Premature Infant Data Collection Form and Early Feeding Skills Assessment Tool. Throughout the study, preterm infants in the experimental group (n=41) were given suck-swallow exercises for 12 minutes once a day before feeding for 14 days. SPSS21 was used to analyze the data. conditions: Premature Infant studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 41 type: ACTUAL name: Sucking and swallowing exercises measure: The early feeding skills assessment tool (EFS) sex: ALL minimumAge: 34 Weeks maximumAge: 37 Weeks stdAges: CHILD facility: Medipol University city: Istanbul state: Beykoz zip: 34810 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06371430 id: Biointelligent Technology Syst briefTitle: Bone Bioactive Liquid Efficiency in Improving Dental Implant Osteointegration Oral Soft Tissue Hellingand Oral Surgery acronym: BBLIS overallStatus: RECRUITING date: 2021-04-14 date: 2024-02-14 date: 2024-06-14 date: 2024-04-17 date: 2024-04-17 name: Biointelligent Technology Systems SL class: INDUSTRY name: Universidad Pública de Navarra name: Dasman Diabetes Institute briefSummary: The investigators implanted 264 Galaxy TS implants (with or without BBL) in 33 patients across both jaws. Implant stability and osseointegration were assessed using Initial Stability Quotient (ISQ) measurements, computed tomography (CBCT) scans and pain evaluations at various intervals post-surgery. Further, implant surfaces were examined using scanning electron microscopy (SEM) and atomic force microscopy (AFM). In vitro studies evaluated the efficacy of BBL on dental pulp pluripotent stem cells (DPPSCs) osteogenesis, and inflammatory factor modulation in human macrophages. conditions: Wound Healing Disorder conditions: Wounds and Injuries conditions: Wound Surgical studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 33 type: ESTIMATED name: Dental Implant insertion and tooth extraction measure: ISQ measurements measure: Pain measure: CBCTs analysis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Biointelligent Technology Syst status: RECRUITING city: Barcelona zip: 08009 country: Spain name: Maher Atari, PhD role: CONTACT email: matari@biointelligentsl.com lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06371417 id: RAY902CT briefTitle: Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2026-06-30 date: 2026-06-30 date: 2024-04-17 date: 2024-04-17 name: Chugai Pharmaceutical class: INDUSTRY briefSummary: This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP). conditions: Antiphospholipid Syndrome (APS) conditions: Bullous Pemphigoid (BP) conditions: Behçet's Syndrome (BS) conditions: Dermatomyositis (DM) conditions: Immune-mediated Necrotizing Myopathy (IMNM) conditions: Immune Thrombocytopenia (ITP) studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 144 type: ESTIMATED name: RAY121 measure: Adverse events (AEs) measure: RAY121 concentration measure: AUCτ measure: Cmax measure: Cmin measure: Active C1s measure: Total C1s measure: Complement activity (classical pathway) measure: Anti-RAY121 antibodies sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Oregon Health & Science University city: Portland state: Oregon zip: 97239 country: United States lat: 45.52345 lon: -122.67621 facility: Hokkaido University Hospital city: Sapporo state: Hokkaido zip: 060-0808 country: Japan lat: 43.06667 lon: 141.35 facility: Tohoku University Hospital city: Sendai state: Miyagi zip: 980-8574 country: Japan lat: 38.26667 lon: 140.86667 facility: Osaka University Hospital city: Suita state: Osaka zip: 565-0871 country: Japan lat: 34.76143 lon: 135.51567 facility: Hamamatsu University Hospital city: Hamamatsu state: Shizuoka zip: 431-3192 country: Japan lat: 34.7 lon: 137.73333 facility: Toho University Omori Medical Center city: Ota-ku state: Tokyo zip: 143-8540 country: Japan lat: 36.3 lon: 139.36667 hasResults: False
nctId: NCT06371404 id: 2000037129 briefTitle: Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2030-06-01 date: 2031-06-01 date: 2024-04-17 date: 2024-04-17 name: Yale University class: OTHER briefSummary: The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these disorders. We will examine relationships between HDAC6 and clinical variables of interest. Findings could direct treatment development. conditions: Alcohol Use Disorder conditions: Post Traumatic Stress Disorder studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: RETROSPECTIVE count: 150 type: ESTIMATED name: Bavarostat measure: HDAC6 expression in people with Post-Traumatic Stress Disorder measure: HDAC6 expression in people with Alcohol use Disorder sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yale University city: New Haven state: Connecticut zip: 06518 country: United States name: Kelly Cosgrove, PhD role: CONTACT phone: 203-737-6969 email: kelly.cosgrove@yale.edu name: Marc Grasso, Ba role: CONTACT phone: 2037377074 email: marc.grasso@yale.edu name: Kelly Cosgrove, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.30815 lon: -72.92816 hasResults: False
nctId: NCT06371391 id: 2023-02077 briefTitle: Environmental and Occupational Noise Exposure in Relation to Incidence of Type 2 Diabetes overallStatus: ACTIVE_NOT_RECRUITING date: 1992-01-01 date: 2013-12-31 date: 2026-12-31 date: 2024-04-17 date: 2024-04-19 name: Karolinska Institutet class: OTHER name: The Swedish Research Council briefSummary: Large parts of the population are exposed to traffic noise, particularly in urban areas, and high noise levels occur in many workplaces. The aims of this project are to estimate exposure-response relationships for incidence of type 2 diabetes (T2D) related to long-term exposure to road traffic, railway and aircraft noise, as well as occupational noise. Furthermore, mediation by sleep disturbances and overweight/obesity is investigated, as well as interactions with air pollution and clinical biomarkers, to elucidate important etiological pathways. The project is based on pooled analyses of nine Scandinavian cohorts, totally including more than 300 000 individuals. Detailed longitudinal exposure to traffic noise from different sources, air pollutants and greenness, as well as occupational exposures, are estimated with state-of-the-art methods and supplemented with questionnaire and registry data on risk factors as well as clinical measurements. Incidence of T2D is assessed by combining information from medical examinations, high quality registers, questionnaires and biomarker measurements. Population attributable risks are estimated by combining population data on exposure with information on exposure-response relationships. In several aspects the project is unique and addresses questions which have never been studied before. Our results will provide important guidance for prioritization of preventive measures to promote health sustainable urban development and safe workplaces. conditions: Environment Related Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 300000 type: ESTIMATED name: No intervention measure: Type 2 diabetes (T2D) sex: ALL minimumAge: 16 Years maximumAge: 98 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06371378 id: gastric residual volume briefTitle: Effect of Different Peep Values on Gastric Residual Volume overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-05 date: 2024-06-01 date: 2024-09-01 date: 2024-04-17 date: 2024-04-19 name: Ankara City Hospital Bilkent class: OTHER briefSummary: The aim of this study was to predict the effect of gastric antrum diameter before extubation on intra-abdominal pressure changes and consequently on the risk of pulmonary aspiration in patients undergoing elective spinal surgery under general anaesthesia in the prone position in the Neurosurgery Operating Theatre of the Ministry of Health Ankara City Hospital and to take precautions accordingly. Gastric antrum diameter and intraabdominal pressure measurements may contribute to the improvement of anaesthetic practice by reducing the risk of pulmonary aspiration and additional complications. conditions: Respiratory Aspiration of Gastric Content studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 90 type: ESTIMATED name: PEEP 0 name: PEEP 4 name: PEEP 8 measure: Gastric antrum diameter measure: Intraabdominal pressure (IAP) measurement measure: gastric volume measurement measure: Vital parameters Pulse oximetry (%) measure: Vital parameters systolic and diastolic blood pressure (mmHg) measure: Vital parameters heart rate (beats/minute) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara City Hospital city: Ankara state: Çankaya country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06371365 id: KMUHIRB-E(II)-20220204 briefTitle: Adverse Events for Free Flap Surgery in Head and Neck Cancer overallStatus: COMPLETED date: 2022-10-19 date: 2023-09-24 date: 2023-09-24 date: 2024-04-17 date: 2024-04-18 name: Kaohsiung Medical University class: OTHER name: Kaohsiung Medical University Chung-Ho Memorial Hospital briefSummary: This is a cohort study collecting patients with head and neck cancer who underwent free flap surgery at a single medical center between January 2019 and January 2022. conditions: Surgical Flaps conditions: Flap Failure Risk Factors conditions: Hematoma Risk Factors conditions: Thrombosis Risk Factors studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 540 type: ACTUAL name: Free Flap surgery measure: Number of participants with flap failure measure: Number of participants with hematoma measure: Number of participants with thrombosis sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kaohsiung Medical University Chung-Ho Memorial Hospital city: Kaohsiung country: Taiwan lat: 22.61626 lon: 120.31333 hasResults: False
nctId: NCT06371352 id: JagiellonianU73 briefTitle: Effect of Intermittent and Continuous Theta Burst Stimulation on Sleep, Daytime Sleepiness, and Fatigue in Depression overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-12 date: 2027-05 date: 2024-04-17 date: 2024-04-17 name: Jakub Antczak class: OTHER name: Institute of Psychiatry and Neurology, Warsaw briefSummary: Intermittent and continuous theta-burst stimulation (iTBS and cTBS respectively) are the newer modalities of transcranial magnetic stimulation with documented efficacy in treatment of depressed mood but with conflicting results regarding their efficacy in treatment of other symptoms of depression such as insomnia, daytime sleepiness and fatigue. This study will investigate the efficacy of iTBS over the left dorsolateral prefrontal cortex (DLPFC) and cTBS over the right DLPFC, compared to sham stimulation, in treatment of insomnia, daytime sleepiness and fatigue in depression. conditions: Unipolar Depression conditions: Bipolar Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, randomized, sham-controlled clinical trial in parallel design primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Placebo intervention will be delivered with a sham-coil for magnetic stimulation, which looks identical and elicits similar sounds as the coil used for active stimulation, but induces only negligible magnetic field. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: iTBS name: cTBS name: Sham measure: Beck Depression Inventory 2 measure: Pittsburgh Sleep Quality Index measure: Brief Psychiatric Rating Scale measure: Epworth Sleepiness Scale measure: Fatigue Assessment Scale measure: Quality of Life in Depression Scale measure: Sleep propensity non-rapid eye movement 1 sleep stage measure: Sleep propensity non-rapid eye movement 2 sleep stage sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Psychiatry and Neurology city: Warsaw zip: 02957 country: Poland name: Bogdan Stefanowski role: CONTACT phone: +48 22 45 82 532 email: bstefanowski@ipin.edu.pl name: Jakub Antczak, MD role: CONTACT phone: +48 12 400 25 50 email: jakub.antczak@uj.edu.pl lat: 52.22977 lon: 21.01178 hasResults: False
nctId: NCT06371339 id: 23 VADS 03 briefTitle: Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases acronym: THIDOS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-06 date: 2024-04-17 date: 2024-04-17 name: Institut Claudius Regaud class: OTHER name: Laboratoire IJCLab briefSummary: This is a pilot, single-center, prospective, open-label clinical investigation of a medical device (ambulatory gamma camera " MoTI " (Mobile Therapy Imager)) for patients with hyperthyroidism (Graves' disease, toxic nodule and toxic multiheteronodular goiter) for whom 131I treatment is indicated.
20 patients will be included in the study. conditions: Hyperthyroidism studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 20 type: ESTIMATED name: Additional acquisitions with the investigational gamma-camera " MoTI ". measure: The clinical feasibility of using an ambulatory gamma camera. measure: The level of acceptance of the gamma camera by operators for carrying out examinations measure: The quality of the images for the expected clinical use measure: The ability of the gamma camera to generate images compatible with the Picture Archiving and Communication System (PACS) measure: The quality of the images obtained with the ambulatory gamma camera compared with those obtained during the standard examination (i.e. gamma camera used in the department, Syngula) measure: The 131I fixation rates will be measured in percent at different times. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IUCT-O city: Toulouse country: France name: Slimane ZERDOUD role: CONTACT phone: 05 31 15 56 28 email: zerdoud.slimane@iuct-oncopole.fr lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06371326 id: BJQLZT002004 briefTitle: A Study of ZT002 Injection in Participants With Overweight or Obesity overallStatus: ENROLLING_BY_INVITATION date: 2023-11-21 date: 2024-08-30 date: 2024-09-30 date: 2024-04-17 date: 2024-04-17 name: Beijing QL Biopharmaceutical Co.,Ltd class: INDUSTRY briefSummary: This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity. conditions: Overweight or Obesity studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 28 type: ESTIMATED name: ZT002 Injection name: Placebo measure: Safety and tolerability of a multiple escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in MAD Cohorts. Number of participants with treatment-emergent adverse events. measure: Safety and tolerability of a multiple escalation dose of ZT002 through the incidence severity of serious adverse events in MAD Cohorts. Number of participants with serious adverse events. measure: The Pharmacokinetics (PK) profile of a multiple escalation dose of ZT002 in participants with overweight or obesity. measure: The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in participants with overweight or obesity. measure: The anti-drug antibody (ADA) response through testing serum or plasma of the participants post-dosing. sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: First Affiliated Hospital of Bengbu Medical College city: Bengbu country: China lat: 32.94083 lon: 117.36083 hasResults: False